Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with ...

First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® RareFDA granted Egetis a Rare…